Pulsed field ablation versus conventional thermal ablation for paroxysmal atrial fibrillation: 4-year outcomes in the ADVENT-LTO study.

Name: Αlpha¹ Rigor Record — Pulsed field ablation versus conventional thermal ablation for paroxysmal atrial fibrillation: 4-year outcomes in the ADVENT-LTO study.
Item: Pulsed field ablation versus conventional thermal ablation for paroxysmal atrial fibrillation: 4-year outcomes in the ADVENT-LTO study.
Rating: 96
Author: Αlpha¹

Reddy VY, Gerstenfeld EP, Mountantonakis SE, Patel C, Ellenbogen KA, Harding JD, Gibson DN, Natale A, Waks JW, Calkins H, Gupta SK, Woods CE, Whang W, Daccarett M, Cuoco FA, Delurgio DB, Richards E, Martens MD, Sutton B, Mansour M, ADVENT-LTO Study Investigators

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.75★ (Weak), 0 critical, 4 high issues for “Pulsed field ablation versus conventional thermal ablation for paroxysmal atrial fibrillation: 4-year outcomes in the ADVENT-LTO study.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsOverstated claim−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingStudy design partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced5 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions overstated beyond the evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Study-design details incomplete (controls, blinding, power)Assessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper is a well-conducted observational extension of a randomized trial, with strong reporting of demographics, ethics, resources, and statistical methods. The main weakness is the lack of a power analysis and incomplete specification of inclusion/exclusion criteria for the extension, which limits the strength of causal claims. Minor copyedit issues and an internal inconsistency in the number of reenrolled patients should be corrected.

Both reviewers classified the study as interventional, which was adopted. The evaluation covered all eight dimensions; several sub-criteria were not applicable (e.g., animal housing, cell lines). The statistics verification recomputed only 4 tests consistently; this is partial coverage and does not validate all reported statistics. The reviewers diverged slightly on reporting guideline (one rated it adequate, the other inadequate), but the overall dimension remains a pass.

5 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 4 tests: 4 consistent, 0 inconsistent; 4 via agent-written checks.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites multiple randomized trials and large observational studies, acknowledges both strengths and limitations of prior work, and logically motivates the need for long-term follow-up. The rationale for the study is clearly linked to the objective of assessing 4-year outcomes, and limitations of prior studies (e.g., 1-year follow-up) are explicitly addressed.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research on PFA safety and efficacy, and identifies the gap of limited long-term outcome data.

Evidence

direct quote[Introduction, paragraph 2]

“Preclinical and early clinical studies demonstrated the safety of PFA on pulmonary vein tissue, phrenic nerves and the esophagus – . Most notably, the clinical safety of PFA has been established in large-scale, center-reported studies of the pentaspline PFA catheter—including the European-centric MANIFEST-17K study of 17,642 patients and the US-centric MANIFEST-US study of 41,698 patients—together demonstrating no pulmonary vein stenosis, permanent phrenic nerve injury or atrio-esophageal fistula , .”